Menu
Not yet recruiting NCT05021627

Cardiac Autonomic Nerve Improvement and Pacemaker Therapy in Patients With Sinus Bradycardia

No phase Interventional Sinus Bradycardia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cardiac autonomic nerve modification, Pacemaker implantation.
Who it may be relevant to
Registry conditions: Sinus Bradycardia. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Multicenter Randomized Controlled Study of Cardiac Autonomic Nerve Improvement and Pacemaker Therapy in Patients With Sinus Bradycardia

Overview

This is a multicenter randomized controlled study. By comparing patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation and pacemaker therapy, and long-term follow-up to evaluate its safety and effectiveness after surgery, in order to evaluate the safety and effectiveness of cardiac autonomic ganglion ablation in the treatment of sinus bradycardia.

Interventions

  • Procedure Cardiac autonomic nerve modification
    Patients with sinus bradycardia undergoing cardiac autonomic ganglion ablation. Specific anatomic ablation of the 4 major left atrial GP and aorta-superior vena cava (Ao-SVC) GP was performed. Briefly, catheter ablation was performed under the guidance of an electroanatomic mapping system (CARTO,BiosenseWebster,DiamondBar,California). After completed the electroanatomic mapping of the left atrium was complete and pulmonary vein (PV) ostia identified, presumed GP clusters were ablated 1 to 2cm ou
  • Procedure Pacemaker implantation
    Patients with sinus bradycardia received pacemaker implantation. The patient lay flat on the bed, puncture the subclavian vein and insert two guide wires. Cut the skin under the guide wire to make a skin bag, and stop bleeding accurately to avoid continuous bleeding of the skin bag. The pacemaker electrode is inserted into the heart cavity by guiding the guide wire, one is placed in the ventricle and the other in the atrium, and the corresponding parameters of the electrode, such as pacing thres

Primary outcome measures

  • Symptom score after operation [Time frame: 48 months]
Secondary outcome measures (2)
  • Quality of life score [Time frame: 48 months]
  • Psychological quality score [Time frame: 48 months]

Eligibility criteria

Inclusion criteria

  • Aged 18 to 80 years old;
  • Symptomatic sinus bradycardia;
  • Not meet the class I indications for pacemaker implantation.

Exclusion criteria

  • Structural heart disease, heart surgery history;
  • Drug-induced SB, sinus pause >2.0 s, positive atropine test, corrected sinus node recovery time (cSNRT) >525 ms;
  • Any atrial or ventricular arrhythmia, or a history of ablation procedures to treat atrial tachyarrhythmias;
  • With Significant congenital heart disease, ejection fraction was <40% measured by echocardiography;
  • Allergic to contrast media;
  • Contraindication to anticoagulation medications;
  • Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive disease (COPD);

9\. Poor general health; 10.Life expectancy less than 6 months.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05021627 · Chest 18

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗